22 22

Cited 0 times in

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

 Mi Jeong Kwon  ;  Jeong Eon Lee  ;  Joon Jeong  ;  Sang Uk Woo  ;  Jinil Han  ;  Byeong-il Kang  ;  Jee-Eun Kim  ;  Youngho Moon  ;  Sae Byul Lee8  ;  Seonghoon Lee6  ;  Yoon-La Choi3  ;  9  ;  10  ;  Youngmi Kwon11  ;  Kyoung Song12  ;  Gyungyub Gong13* and Young Kee Shin 
 Frontiers in Oncology, Vol.9 : 667, 2019 
Journal Title
 Frontiers in Oncology 
Issue Date
Asian population ; GenesWell BCT score ; concordance ; early breast cancer ; oncotype DX recurrence score ; risk classification
Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared. Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%) as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer. Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.
Files in This Item:
T201903216.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.